Sabine Hazan, MD, as the first woman accepted into the University of Florida as a Clinical Gastroenterology Fellow, is a pioneer in the medical field. She has published articles in numerous prestigious medical journals, and is the Series Editor on the microbiome for Practical Gastroenterology, a peer review journal that reaches 18,000 gastroenterologists.
She is a speaker for the World Congress of Digestive Disease, MAGI, Microbiome Congress, ILADS, TACA, International Drug Discovery Science and Technology Conference and NIST (National Institute of Standards and Technology).
As a specialist in gastroenterology, internal medicine, and hepatology, Dr. Hazan has used her medical expertise in many regards over the last two decades.
Dr. Hazan is the CEO of Ventura Clinical Trials, where she has 20+ years experience leading clinical trials for cutting-edge research on various medical issues and has done over 300 clinical trials for pharmaceutical companies. Since March 2020, she has been at the forefront of COVID-19 research, leading ongoing FDA-approved clinical trials for treatment and prophylaxis on Hydroxychloroquine, Z-Pak, vitamin C, vitamin D, zinc, and Ivermectin.
She is also the founder & CEO of Progenabiome, a genetic sequencing research laboratory, she leads 35+ studies investigating the role of the gut flora in various diseases.
Through their study exploring the role of the gut flora in COVID-19, Progenabiome became the first lab worldwide to detect SARS-CoV-2 from patient fecal samples by Whole Genome Sequencing and the lab that showed a susceptibility marker for COVID in the microbiome.
Dr Hazan is mastering familial fecal transplant showing hope for kids with Autism.
Learn more: ProgenaBiome.com